Proficiency Testing/EQA / 2024 Surveys / Immunology and Flow Cytometry / Flow Cytometry Help Please log in to determine if you are eligible to purchase PT Programs. B-ALL MEASURABLE (MINIMAL) RESIDUAL DISEASE - BALL Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS). Analyte Challenges per Shipment Number of Shipments B-ALL measurable (minimal) residual disease 3 Two shipments per year Program BALL is intended for laboratories that perform measurable (minimal) residual disease (MRD) testing (rare event analysis) for B lymphoblastic leukemia/lymphoma. The cases presented will be a mixture of Children's Oncology Group (COG) approved B-ALL MRD method and laborotory developed assays. Participation in this program alone does not satisfy PT requirements for laboratories performing more general analysis of leukemia/lymphoma specimens. Program Information Two 1.1-mL specimens containing a cell line/whole blood mixture simulating B lymphoblastic leukemia/lymphoma measurable (minimal) residual disease One online case consisting of gated dot plots This program has stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada. Shipping Schedule Shipment A: January 10 Shipment B: July 10 Guest Log in/Register Customers Who Bought This Item Also Bought Color Atlas of Flow Cytometry VIEW DETAILS >